Protocol [V01-CBT-401] Bausch Health Americas, Inc.
Page 1 of 49  
Version 3.0 09/13/2021 CONFIDENTIALClinical Study Protocol
A Prospective Study Evaluating the Safety and Effectiveness of the CLEAR + 
BRILLIANT TOUCH¬£diode laser 1440-nm and 1927-nm Combination Wavelength 
Treatment
Protocol Number : V01-CBT-401
Sponsor
Bausch Health Americas, Inc. 
400 Somerset Corporate BoulevardBridgewater, NJ [ZIP_CODE]
Main Office: ([PHONE_17489]
Sponsor Contact: 
[INVESTIGATOR_407677]. Clinical Trial Manager
Protocol Version / Date: Version 1.0, 04/07/2021
Version 2.0, 06/22/2021
Version 3.0, 09/13/2021
The study will be conducted according to the protoc ol and in compliance with EN ISO [ZIP_CODE]:2020   
Clinical Investigation of Medical Devices for Human Subjects ‚ÄìGood Clinical Practices, International 
Conference of Harmonization Good Clinical Practice Guidelines and all other applicable regulatory 
requirements and standards.
CONFIDENTIALITY STATEMENT
THE INFORMATION PROVIDED IN THIS STUDY PROTOCOL IS INTENDED FOR REVIEW BY [CONTACT_675083](S), ALL RESEARCH RELATED PERSONNEL, IRBS/ETHICS 
COMMITTEE(S) AND HEALTH AUTHORITIES. INFORM ATION PROVIDED AND CAPTURED IN THIS 
PROTOCOL IS STRICTLY CONFIDENTIAL AND WILL ONLY BE DISCLOSED WITH WRITTEN 
CONSENT FROM THE SPONSORS.
The Sponsor, Bausch Health Americas, Inc. , is funding this clinical investigation. 
1&7
Protocol [V01-CBT-401] Bausch Health Americas, Inc.
 
Page 3 of 49  
Version 3.0 09/13/2021 CONFIDENTIALStudy Administrative Structure
Study Title: A Prospective, Study Evaluating the Safety and Effectiveness of the 
CLEAR + BRILLIANT TOUCH¬£diode laser 1440-nm and 1927-nm 
Combination Wavelength Treatment
Medical Monitor
Contract Research Organization (CRO)
SGS Stephens, Inc
Cheryl Vaughan, Clinical Investigator
SGS Stephens, Inc.            
[ADDRESS_1168802]
Dallas, TX [ZIP_CODE]
1 All contractual and financial agreements between clinical site and the Sponsor will be administrated by [CONTACT_841225] a minimum by [CONTACT_841226].
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 5 of 49  
Version 3.0 09/13/[ADDRESS_1168803] OF ABBREVIATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 ABBREVIATION/TERM DEFINITION 
AE Adverse Event 
CFR Code of Federal Regulations 
CRF Case Report Form 
EDC Electronic Data Capture  
EOS End of Study 
FDA Food and Drug Administration 
FDF Financial Disclosure Form 
GAIS Global Aesthetic Improvement Scale 
GCP Good Clinical Practice 
ICF/ICD Informed consent form/ Informed consent document 
ICH International Conference on Harmonization 
IEC Independent Ethics Committee 
IRB Institutional Review Board 
ITT Intent To Treat 
IQIS Investigator Quartile Improvement Score 
MTZ Microthermal treatment zone 
PI [INVESTIGATOR_841189] [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 6 of 49  
Version 3.0 09/13/[ADDRESS_1168804] OF ABBREVIATIONS ......................................................................................................... ............................... 5  
1. STUDY SYNOPSIS ............................................................................................................. ................................... 9  
2. INTRODUCTION: BACKGR OUND INFORMATION ....................................................................................... ....... 11  
2.1   DEVICE DESCRIPTION  .............................................................................................................................. ............... 12  
2.1.1   Mechanical Specifications ............................................................................................. ........................... 13  
2.1.2   Laser Safety Standards ................................................................................................ ............................. 13  
2.1.3   Study Device Accountability ........................................................................................... .......................... 14  
3. STUDY OBJECTIVE: ........................................................................................................... ................................ 14  
4. STUDY DESIGN AND ENDPOINTS ................................................................................................. ..................... 14  
4.1   DESCRIPTION OF STUDY DESIGN : ............................................................................................................................. . 14 
4.2   STUDY ENDPOINTS  .............................................................................................................................. .................. 14  
4.2.1   Primary Endpoint ...................................................................................................... ................................ 14  
4.2.2   Secondary Endpoint .................................................................................................... .............................. 15  
4.2.3   Safety Endpoints ...................................................................................................... ................................. 15  
4.2.4   Exploratory Endpoints ................................................................................................. ............................. 15  
5. INVESTIGATOR SELECTION AND STUDY POPULATION: ............................................................................... ...... [ADDRESS_1168805] Withdrawal or Termination.......................................................................... ............ 18  
6.   STUDY PROCEDURES AND SCHEDULE: ........................................................................................... ................. 19  
6.1   INFORMED CONSENT  .............................................................................................................................. ............... 19  
6.2   PRE-PROCEDURE  .............................................................................................................................. .................... 19  
6.3   STUDY PROCEDURE  .............................................................................................................................. ................. 20  
6.4   FOLLOW -UP PROCEDURE  .............................................................................................................................. .......... 21  
6.5   DATA COLLECTION  .............................................................................................................................. .................. 21  
6.5.1 Photography.............................................................................................................. ................................. 22  
6.5.2   Specimens ............................................................................................................. .................................... 22  
6.6   FINAL STUDY VISIT .............................................................................................................................. .................. 22  
6.7   STUDY COMPLETION  .............................................................................................................................. ................ 23  
6.8   SCHEDULE OF EVENTS TABLE .............................................................................................................................. ..... 23  
7.   EVALUATION TOOLS ......................................................................................................... .............................. 25  
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 7 of 49  
Version 3.0 09/13/[ADDRESS_1168806] 2D PHOTOGRAPHY  .......................................................................................... 25  
7.2   INVESTIGATOR EVALUATIONS QUARTILE IMPROVEMENT SCORE  ...................................................................................... 25  
7.3   PUNCH BIOPSIES  .............................................................................................................................. ..................... 26  
7.4   VISUAL ANALOG SCALE (VAS) ......................................................................................................................... ........ [ADDRESS_1168807] MODIFIED GLOBAL AESTHETIC IMPROVEMENT SCORE  ...................................................................................... 27  
7.7   INDEPENDENT PHOTOGRAPHIC ASSESSMENTS  ............................................................................................................. 27  
8.   ASSESSMENT OF SAFETY ..................................................................................................... ........................... 28  
8.1   SPECIFICATION OF SAFETY PARAMETERS  .................................................................................................................... 28  
8.1.1   Definition of Serious  Adverse Events (SAE) ............................................................................ ................... 28  
8.1.2   Definition of Adverse Events (AE) ..................................................................................... ........................ [ADDRESS_1168808] (UADEs) ............................................................. ........ 29  
8.1.4   Definition of De vice Malfunction ...................................................................................... ........................ 29  
8.2   ADVERSE EVENT / DEVICE MALFUNCTION REPORTING  ................................................................................................. 29  
8.3   CLASSIFICATION OF ADVERSE EVENTS  ........................................................................................................................ 30  
8.4   RELATIONSHIP TO THE STUDY DEVICE AND /OR PROCEDURE  ............................................................................................ 30  
8.5   TERMINATION OF STUDY RULES FOR SAFETY  ............................................................................................................... 31  
9.   RISKS AND BENEFITS ....................................................................................................... ............................... 31  
9.1   BENEFITS  .............................................................................................................................. ............................... 31  
9.2   RISKS .............................................................................................................................. .................................... 31  
9.2.1   Expected Responses .................................................................................................... ............................. 31  
9.2.2   Unexpected  Responses .................................................................................................. ........................... 32  
9.2.3   Biopsy Risks .......................................................................................................... .................................... 32  
9.3   MITIGATION OF RISKS .............................................................................................................................. .............. 33  
10.   STATISTICS............................................................................................................... ..................................... 33  
10.1    STATISTICAL ANALYSIS POPULATIONS AND DEMOGRAPHICS  ......................................................................................... 33  
10.2    STATISTICAL ANALYSIS PLAN (SAP) ........................................................................................................................ 34 
10.2.1 Descriptive Statistical Summary ........................................................................................ ....................... 34  
10.2.2 Additional Analysis .................................................................................................... ............................... 34  
10.2.3 Minimization of Bias and Po tential Confounding Factors ................................................................. ....... 35  
11.   SOURCE DOCUMENTS AND A CCESS TO DATA/DOCUMENTS ........................................................................ [ADDRESS_1168809] KEEPI[INVESTIGATOR_1645]......................................................................................... ............. 38  
14.1    DATA COLLECTION AND MANAGEMENT  ................................................................................................................... 38  
14.2    STUDY RECORDS RETENTION  .............................................................................................................................. ... 39 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 8 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL 14.3    PROTOCOL DEVIATIONS  .............................................................................................................................. .......... 39  
14.4    PUBLICATIONS AND DATA SHARING  ........................................................................................................................ 40  
15. LITERATURE REFERENCES ..................................................................................................... .......................... 41  
APPENDIX SECTION .............................................................................................................. ................................ 42  
APPENDIX A: GLOGAU PHOTODAMAGE SCALE ................................................................................................................... 42  
APPENDIX B: FITZPATRICK WRINKLE AND ELASTOSIS SCALE .................................................................................................. 42  
APPENDIX C: FITZPATRICK SKIN TYPE .............................................................................................................................. . 43 
APPENDIX D: SERIOUS ADVERSE EVENT / UNANTICIPATED ADVERSE DEVICE EFFECT REPORT FORM ............................................. 44  
APPENDIX E: DEVICE MALFUNCTION REPORT FORM ........................................................................................................... 47  
APPENDIX F: PATIENT SKIN RESPONSE SEVEN -DAY DIARY .................................................................................................... 49  
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 9 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL 1. STUDY SYNOPSIS 
Name [CONTACT_790]/Company Bausch Health Americas, Inc.  
Name [CONTACT_841259] + BRILLIANT TOUCH¬£ diode laser 1440-nm and 1927-nm  
Title of Study A Prospective, Single-Center Study Evaluating the Safety and Effectiveness of 
the CLEAR + BRILLIANT TOUCH¬£ diode laser 1440-nm and 1927-nm 
Combination Wavelength Treatment.  
Number of Clinical Centers Single Center  
Study Design This is a prospective study of up to 30 subjects designed to assess the safety 
and ef fectiveness of a non-ablative fractional laser combination wavelength 
treatment  for general resurfacing of photoa ged skin. All study subjects will b e 
treated on the whole face with the CLEAR + BRILLIANT TOUCH¬£ 1440- nm and 
1927 -nm handpi[INVESTIGATOR_6928]. Subjects will be treated with a consecutive series of four 
(4) treatments spaced 1  month apart, along with follow- up study visits at one (1) 
and three (3) months after final treatment. 
Study Population To be eligible for the study, the subjects  must have mild (I) to moderate (II) 
photoaging  by [CONTACT_841227] , no more than fine wrinkles and mild 
elastosis  by [CONTACT_841228] (Class I-II, Score 1-6). Both 
males and females will be considered, be tween the ages 18 and 65 years and 
Fitzpatrick skin Types I -VI with 70% skin types I-III and 30% skin types IV- VI. 
 
Number of subjects: Up  to 30 subjects who meet all stu dy inclusion/exclusion 
criteria will be considered for entry. 
Study Objective The objective is to evaluate the effectiveness and safety of the CLEAR + 
BRILLIANT TOUCH¬£ diode laser combination treatment of 1440- nm and 1927-
nm.  
Study Endpoints Primary Effectiveness Endpoint: improvemen t in the appearance of at least one 
measurement of photoaging damage  (fine wrinkles, skin texture, 
dyschromia/pi[INVESTIGATOR_2517], skin radiance, pore size or overall appearance) by [CONTACT_841229] 2D 
baseline photograph captured via Canfield VISIA CA system and the [ADDRESS_1168810] final treatment photograph. Reported percent change in improvement. 
Secondary Effectiveness Endpoint : improvement in the appearance of at least 
one measurement of photoaging damage ( fine wrinkles, skin texture, 
dyschromia/pi[INVESTIGATOR_2517], skin radiance, pore size and overall appearance) by [CONTACT_841230] 2D 
baseline photograph captured via Canfield VISIA CA system to [ADDRESS_1168811] 
final treatment photograph. Reported percen t change in improvement.  
Safety :  
- Serious Adverse Events (SAEs) related and unrelated to the treatment 
procedure or to the CLEAR + BRILLIANT TOUCH¬£ diode laser system. 
- The severity of post-treatment skin responses:  
‚Ä¢ Immediate post-treatment erythema and edema.  
‚Ä¢ Prolonged post- treatment erythema, edema, dryness/flakiness, 
hypopi[INVESTIGATOR_371], hyperpi[INVESTIGATOR_293644], blistering, scarring. 
- The evaluation of pain and discomfort immediately after the treatment 
(within 60 minutes) as reported by [CONTACT_1175] a visual analog scale 
(VAS) 
  
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 10 of 49  
Version 3.0 09/13/[ADDRESS_1168812] Modified Global Aesthetic Impr ovement Scale (GAIS) comparing their 
overall appearance in photos at [ADDRESS_1168813] treatments. 
Five (5) patient s will have [ADDRESS_1168814] treatments (location on the 
face at discretion of investigating physician either pre-auricular or at temple 
hairline. If face location unattainable the forearm exposed to photoaging may be 
used as an alternate biopsy location ). 
Blinded Investigator:  analysis of unmarked 2D photo sets via Canfield clinical 
system. Reviewers will select the order of baseline and post treatment one-
month photos. Then based on their selection assess photos for percentage 
improvement in photoaging damage usin g the quartile improvement scale and 
score [ADDRESS_1168815] order sets. 
Blinded Investigator:  analysis of unmarked 2D photo sets via Canfield clinical 
system. Reviewers will select the order of baseline and post treatment three-
months photos. Then based on their se lection assess phot os for percentage 
improvement in photoaging damage usin g the quartile improvement scale and 
score [ADDRESS_1168816] order sets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 11 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL 2. INTRODUCTION: BACKGROUND INFORMATION 
 
Skin is susceptible to aging, much like all the other organs of the body. There are two 
different processes at work that lead to skin alterations. Intrinsic aging is a chronological, 
biological progression of degenerative chan ges associated with time, gravity, hormones, 
and genetics. Exposure to environmental fact ors contributes signif icantly to the aging 
process of the skin. The second process called  extrinsic aging is a direct consequence of 
external elements, mainly induced by [CONTACT_841231] t (UV) radiation, and 
hence called photoaging.[ADDRESS_1168817], 
and arms. Alterations in th e skin from photoaging incl ude uneven pi[INVESTIGATOR_371], 
telangiectasia, wrinkles, roughness (textural changes), and occur in both the epi[INVESTIGATOR_108208].2 Histologically damage to the skin‚Äôs dermal connective tissue occurs because of the 
loss of collagen, elastosis, an d alterations of components in the extracellular matrix.1 
Increased and uneven pi[INVESTIGATOR_841190] a result of changes in 
melanocytes located in the basal epi[INVESTIGATOR_518684].7 
Patients seek out treatment options for both in trinsic and extrinsic ski n concerns for general 
skin resurfacing. Laser treatments fo r photoaging began with ablative CO 2 (10,600 nm) 
lasers, which vaporized the epi[INVESTIGATOR_841191]. These treatments had 
prolonged downtime and an increas ed risk of side effects. Non-ablative lasers were created 
to spare the epi[INVESTIGATOR_841192]; they had a better safety profile; 
however, efficacy was limited.3  
Non-ablative fractional lasers utilize different wavelengths to ablate or coagulate tissue in 
columns or microthermal treatment zones (MTZ s). Tissue is not vaporized and the stratum 
corneum remains intact.6 The skin then heals from both  the edge of the wound and 
underlying tissue. The dermis undergoes necros is leaving a dead space to be filled with new 
collagen and repair of tiss ue related to photoaging.4 The spared areas shortened downtime 
and presented a smaller range of side effects, increasing the safety profile. Fractional 
resurfacing treatments utilizing multiple wavele ngths in a single session over a series of 
treatments has clinical benefits for treating superficial and underlying dermal effects 
associated with photodamage.5 
The CLEAR + BRILLIANT TOUCH¬£ diode laser is a low powered and low density (0.9- 2.5 
watt) non-ablative fractional di ode laser that targets water as its chromophore. The system 
utilizes the principle of fractional photo the rmolysis which means only limited areas of the 
skin are exposed to lase r optical energy at one time. Hea ling time is minimized because the 
fractional photo thermolysis laser affects on ly a pre-determined pe rcentage of the skin 
surface at any one time and does  not cause full epi[INVESTIGATOR_841193]. It can deliver a 1927 nm 
(170 Œºm fixed depth) and 1440 nm (280-390 Œºm depth) wavelength depending upon the 
handpi[INVESTIGATOR_841194] a session.8,[ADDRESS_1168818] and safety of de livering two wavelengths in the same session 
treatment, over a series of four treatments addressing alterations of  photoaging using the 
CLEAR + BRILLIANT TOUCH¬£ fractionated diode laser, will be assessed.  
 
Protocol [V01-CBT-401] Bausch Health Americas, Inc.
Page 12 of 49
Version 3.0 09/13/2021 CONFIDENTIAL2.1   Device Description
The CLEAR + BRILLIANT TOUCH¬Æ System is manufactured by [CONTACT_841232], Inc. ([ADDRESS_1168819] N., Suite 100, Bothell WA  [ZIP_CODE], [LOCATION_003]) and is indicated for use in 
dermatological procedures requiring the coagulation of soft tissue and general skin resurfacing
procedures. The CLEAR + BRIL LIANT TOUCH¬Æ System consis ts of a console and two 
versions of the laser handpi[INVESTIGATOR_13959]. The console co nnects to the facility power source and the 
handpi[INVESTIGATOR_841195], disposable treatment tips. A 
credit key is required to activa te treatments and is inserted into the side of the console. 
Additional details on the CLEAR + BRILLIAN T TOUCH¬Æ System can also be found in the 
CLEAR + BRILLIANT TOUCH¬Æ Laser System User Manual Revision D provided by [CONTACT_429].
The system includes the Original Handpi[INVESTIGATOR_13959] (1440 nm) and the Perm √©a‚Ñ¢ Handpi[INVESTIGATOR_13959] (1927 
nm), allowing for targeted treatment of different tissue depths.
Front and Rear view of the system
Control/Connection/Description Function
1Credit Key Contains treatment credits. Credit Keys are removable and are to be disposed of 
when finished.
2Emergency Stop Switch Stops the laser treatment beam when pre ssed during an emergency. To restart, 
twist the button and release it from the latched Off position.
3Console Houses the electro-mechanical components that operate the system.
4Touch Screen Displays information on operating the system, including system status, progress 
of the self -test, instructions, and general messaging. The Touchscreen is 
interactive: Select by [CONTACT_53737][INVESTIGATOR_841196].
5Power Button Powers on and off the system.
6AC Power Inlet, Network 
Connection, and USB PortsConnects the Console to the Power Cord.
Used by [CONTACT_841233]. Down loads Charting information and used 
by [CONTACT_841233].
7Handpi[INVESTIGATOR_841197], and where the Treatment Tips are attached. Two 
Handpi[INVESTIGATOR_841198]: TheOriginal Handpi[INVESTIGATOR_13959] (1440 nm) in gray, and the 
Perm √©a‚Ñ¢ Handpi[INVESTIGATOR_13959] (1927 nm) in blue.
8Handpi[INVESTIGATOR_841199]. Disconnect using the workable latches.
9Cradle Holds the Handpi[INVESTIGATOR_841200].  Installed Handpi[INVESTIGATOR_841201]- test runs during the initialization of 
the system. This is automatically controlled by [CONTACT_19915].
1
23
45
6
78
9
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 13 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL 2.1.1   Mechanical Specifications 
 
Size 31.75cm (W) x 28.58cm (L) x 27.94cm (H) 
12.5‚Äù (W) x 11.25‚Äù (H) X 11‚Äù (D)  
Weight Approximately 15.5LBS (7kg) 
Power Cord length 3m (10ft) 
Handpi[INVESTIGATOR_841202] 2m (6.6ft) 
 
2.1.2   Laser Safety Standards 
 
The CLEAR + BRILLIANT TOUCH¬Æ System meets applicable electrical and laser safety 
standards (per IEC [ZIP_CODE] series and IEC [ZIP_CODE]-1) for a Class 1C laser. 
The CLEAR + BRILLIANT TOUCH¬Æ System cont ains a Class 1C laser, according to 
IEC/EN [ZIP_CODE]-[ADDRESS_1168820] exposure of laser energy to the eyes. 
Handpi[INVESTIGATOR_841203] l Specifications: 
Original Handpi[INVESTIGATOR_13959] (1440 nm)  
Equipment classification IEC [ZIP_CODE] -1 Class 1  
Handpi[INVESTIGATOR_841204] [ZIP_CODE] -1 Classification Class 1C  ‚Äì Invisible Laser Radiation 
Wavelength  1440 ¬± 20 nm; min:1420 max:1460      
Maximum Power (average)  2.5 W  
Maximum Pulse Energy  9 mJ  
Maximum Pulse Width  3 ms  
Pulse Repetition Rate  < 400 Hz  
 
Perm√©a ‚Ñ¢ Handpi[INVESTIGATOR_13959] (1927 nm)  
Equipment classification IEC [ZIP_CODE] -1 Class 1  
Handpi[INVESTIGATOR_841204] [ZIP_CODE] -1 Classification Class 1C  ‚Äì Invisible Laser Radiation 
Wavelength  1927 ¬± 20 nm; min:1907 max:1947      
Maximum Power (average)  0.9 W  
Maximum Pulse Energy  5 mJ  
Maximum Pulse Width  5 ms  
Pulse Repetition Rate  < 150 Hz  
 
 
 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 14 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL 2.1.3   Study Device Accountability 
 
The Investigator will be responsible for keepi[INVESTIGATOR_841205]. At various time points throughout the study and/or upon 
completion of the study, the Sponsor or Spon sor‚Äôs representative will review and verify 
the Investi gator‚Äôs accountability records .  
 
Credit Keys and disposable Trea tment Tips are used to restri ct access to the device to 
only authorized users. Laser light can only  be produced by [CONTACT_841234] a valid 
Credit Key with availabl e treatment credits is inserted into the Console and a Treatment 
Tip is attached to the Handpi[INVESTIGATOR_13959]. One Credit  Key is loaded with 12 treatment credits. 
The Investigator will be provided with sufficie nt Credit Keys /Treatment Tips to provide 
treatment for subjects enrolled into the stud y. Credit Key lot number and Treatment Tip 
lot number will be recorded for each subject treatment on the CRF.  
 
Following study completion, study devices must be returned to the Sponsor. The 
Sponsor will be responsible for complete study accountability, returns, and reconciliation 
of the returned devices at the conclusion of the study. 
3. STUDY OBJECTIVE:  
 
The objective is to evaluate the effectiv eness and safety of the CLEAR + BRILLIANT 
TOUCH¬£ diode laser combination treatment of 1440-nm and 1927-nm.  
4. STUDY DESIGN AND ENDPOINTS 
4.1   Description of Study Design: 
 
This is a prospective, non-randomized study of  up to 30 subjects designed to assess the 
safety and effectiveness of a non-ablative  fractional combination laser wavelength 
procedure for general resurfacing of photoaged skin. All study subjects will be treated on the whole face with the with the 
CLEAR + BRILLIANT TOUCH¬£ diode laser 1927-nm & 1440-
nm handpi[INVESTIGATOR_6928]. Subjects will be treated with a consecutive series of four (4) treatments 
spaced 1-month apart, along with follow-up st udy visits at one (1) and three (3) months 
after final treatment. As primary and second ary effectiveness endpoints aim to evaluate 
improvement in photoaging damage post-treatme nt as compared to baseline following 
treatment with the FDA-cleared CLEAR + BRILLIANT TOUCH¬Æ System, no control group 
will be utilized. 
 
4.2   Study Endpoints 
 
4.2.1   Primary Endpoint  
 
Primary Effectiveness Endpoint:  improvement in the appearance of any one or 
more measurement of photoaging damage (fine wrinkles, skin texture, 
dyschromia/pi[INVESTIGATOR_2517], skin radiance, pore size and overall appearance) by [CONTACT_841235] 2D baseline 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 15 of 49  
Version 3.0 09/13/[ADDRESS_1168821] final treatment photograph. Reported percent 
change in improvement.  
 
4.2.2   Secondary Endpoint 
 
Secondary Effectiveness Endpoint: improvement in the appearance of any one or 
more measurement of photoaging da mage (fine wrinkles, skin texture, 
dyschromia/pi[INVESTIGATOR_2517], skin radiance, pore size and overall appearance) by [CONTACT_841235] 2D baseline 
photograph and the [ADDRESS_1168822] final tr eatment photograph. Reported percent 
change in improvement.  
 
4.2.3   Safety Endpoints 
 
Serious Adverse Events (SAEs) related an d unrelated to the treatment procedure 
or to the  CLEAR + BRILLIANT TOUCH¬£ diode laser. 
 
The severity of post-treatment skin responses: 
  
x Immediate post-treatment erythema and edema (Visits: 1 and or 2 if 
screening and treatment on same  day, Visits 3, 4 and 5) 
x Prolonged post-treatment erythema, edema, dryness/flakiness, 
hypopi[INVESTIGATOR_371], hyperpi[INVESTIGATOR_371], blistering, scarring. (Visits 6 & 7) 
 
The evaluation of pain an d discomfort immediately after the treatment (within 60 
minutes) as reported by [CONTACT_70579] t on a visual analog scale (VAS).  
 
4.2.[ADDRESS_1168823] Modified Global Aesthetic Im provement Scale (GAIS) comparing their 
own photos at [ADDRESS_1168824] treatments. 
iii. Five (5) patients will have 2-mm pu nch biopsies from area of photoaging 
comparing baseline to [ADDRESS_1168825] treatments (location on face 
at discretion of investigating physician: ei ther pre-auricular or at temple hairline. 
If face location is unatta inable, the forearm, exposed to photoaging may be used 
as an alternate biopsy locati on). Pre- and post-treatment  biopsies must be taken 
from the same general loca tion for each patient. 
iv. Blinded Investigator: analysis of unmark ed 2D photo sets via Canfield clinical 
system. Reviewers will select the order of baseline and post treatment one-
month photos. Then based on their se lection assess photos for percentage 
improvement in photoaging damage using the quartile improvement scale and 
score 0-4. Reported percent change in  improvement of correct order sets. 
v. Blinded Investigator: analysis of unmark ed 2D photo sets via Canfield clinical 
system. Reviewers will select the order of  baseline and post treatment three-
months photos. Then based on their selection assess photos for percentage 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 16 of 49  
Version 3.0 09/13/[ADDRESS_1168826] order sets. 
5. INVESTIGATOR SELECTION AND STUDY POPULATION: 
5.1   Investigator Selection 
 
Investigators will be qualified based on prof essional experience in the diagnosis and 
treatment of photoaged skin in cluding fine and coarse wrinkl es, dyspi[INVESTIGATOR_371], loss of 
tone, texture and elastosis using ener gy-based devices including lasers.  
 
Investigators should be familiar with the ri sks and benefits described in Section 9. 
Investigator training and experience will be dete rmined by [CONTACT_841236]‚Äôs medical training and licensure.  
5.2   Number of Participants 
 
Up to 30 subjects who meet all study/excl usion criteria will be considered for entry. 
Application of the inclusion and exclusion criter ia in the following sections will result in the 
selection of an investigational population which is approximately representative of the intended target population. 
 
5.[ADDRESS_1168827] be obtained.  4. No more than Mild (I) to Moderate (II) classification on Glogau Photodamage 
Scale. 
5. Fitzpatrick skin types I-VI. 
6. Fitzpatrick wrinkle & elastosis scale class I-II, score 1-6 (fine wrinkles and mild 
elastosis). 
7. Ability to read, understand and sign the informed consent form. 
8. Agree not to take any new medications (unless prescribed by [CONTACT_31821]) or undergo any other procedures that may potentially treat 
photodamaged skin (any other aestheti c treatments) during the study. 
 
5.4   Exclusion Criteria  
 
Subjects will be excluded from the study if they meet any of the following criteria. 1.   Pregnant, breastfeeding, or planning  to become pregnant  during the study. 
2    History of any type of al lergic reaction to lidocaine. 
3.   Recent and/or active lo calized or systemic infections. 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 17 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL 4.   Diagnosis/possibi lity of actinic keratosis, melasma, rosacea, or other significant 
skin conditions (e.g. skin c ancer, active infections, co ld sores, open wounds, 
rashes, burns, inflammation eczema, psoriasis). 
5.   Predisposition to keloid formation or excessive scarring. 
6. Diagnosis of a condition that may compromise the immune system, such as: HIV, 
lupus, scleroderma, and/or systemic infections. 
7.   Known sensitivity to light or photosen sitizing agents/medicat ions are being taken. 
8.   Systemic steroids (e.g. prednisone, dexamethasone), which should be rigorously 
avoided prior to and throughout  course of the treatment. 
9.   Use of retinoids less than 2 weeks prio r to or during the study to completion.  
10. Individuals undergoing Accutane‚Ñ¢ treatment or drugs in a similar class.  
11. Having skin that is still recovering fr om a cosmetic procedure: such as a chemical 
peel, or mechanical peel, or laser resurfacing within the previous 6 months. 
12. Having had Botox injections, neurotoxin  injections, or dermal fillers (such as 
collagen) within the past four months. 
13. Sunburn and/or recent sun exposure on the treatment area in the last [ADDRESS_1168828] from safely completing 
all protocol requirements for participation. 
16. Subjects who are unable to communicat e or cooperate with the investigator due 
to language problems, poor mental deve lopment, or impaired cerebral function. 
5.5   Strategies for Recruitment and Retention 
 
The recruitment process planned for this stud y will include any of the following scenarios: 
‚Ä¢ An individual voluntarily sch edules an appointment at the physician‚Äôs office (that in 
the context of this study also functions as th e investigator‚Äôs test site) relating to the 
treatment of photoaging. 
‚Ä¢ The study population may also  be drawn from the investi gator‚Äôs existing database of 
subjects who have expressed an interest in treatment of photoaging.  
‚Ä¢ During the visit, if the physician perceives the subject may satisfy the study 
qualification criteria, the physician will present to the subject the option of being a subject in the study. 
‚Ä¢ If the subject is interested in possibly taking part in the study, the physician ‚Äì now in 
the role of study investigator ‚Äì will personally review the informed consent form with 
the individual and answer an y questions. The individual  may sign the informed 
consent form at that visit or he or she may think about it for a while and sign the 
informed consent form later. No timeline  may be set for the subject to sign the 
consent form. Furthermore, the subject can refuse to participate in the study. 
‚Ä¢ An individual who de cides to sign the consent form and proceed with participation in 
the study will receive a subject ID and proceed to the study qualification phase. 
‚Ä¢ Treatment will include a screening visit, four treatment visits and two follow up visits; 
a total of seven office visits to complete  participation. (Screening visit and first 
treatment may be on same day if no biopsy is taken.) Biopsy patients will have a total 
of eight office visits to in clude an additional biopsy collection at [ADDRESS_1168829] 
treatment #1 for enrollment completion. 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 18 of 49  
Version 3.0 09/13/[ADDRESS_1168830] treatment (Treatment #1) 
following confirmation of eligibility according to  inclusion/exclusion crit eria at the Screening 
Visit and again at  Visit 2 (Treatment #1).  
5.[ADDRESS_1168831] has completed the study when he/s he completes Visit 7 (3-month follow-up). A 
subject who has missed visits or is missing study measurements will remain in the study. 
Subjects who require further follow-up for an adverse event (AE) or adverse device effect 
(ADE) will be followed according to Section 8.2.  The same standard of care will be available for subjects who complete the study as for discontinued subjects (see Section 5.9) if such 
additional care is necessary because of the subj ects‚Äô participation in th e clinical investigation 
and where it differs from that normally ex pected for the medical condition in question. 
5.[ADDRESS_1168832]'s consent, if th e investigator feels it is in the best medical 
interest of the subject. The date and reason for study withdrawal will be indicated on the study exit case report form. Every effort should be made to contact [CONTACT_449367]-up, 
and all such efforts should be documented in the subject ‚Äôs file.  
If the subject withdraws from the study and also  withdraws consent for disclosure of future 
information, no further evaluations will be performed, and no additional data will be 
collected.  The Sponsor may retain and contin ue to use any data co llected before such 
withdrawal of consent. 
5.9.[ADDRESS_1168833] will be discontinued from participation in the study if: 
‚Ä¢ Any clinical adverse event (AE), laborato ry abnormality, intercurrent illness, or 
other medical condition or situation occurs such that continued participation in 
the study would not be in the best interest of the subject. 
‚Ä¢ The subject meets any exclusion criteria (either newly developed or not 
previously recognized). 
Subjects who are withdrawn will not be replaced. 
5.9.[ADDRESS_1168834] is wit hdrawn from study because of 
adverse events they will be provided with the appropriate care under medical supervision.  
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 19 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL 6.   STUDY PROCEDURES AND SCHEDULE: 
 
6.[ADDRESS_1168835] sign and date an IR B-approved consent 
document. The original, signed documents will be kept with these subjects ‚Äô files and copi[INVESTIGATOR_841206]. The informed consent process must be followed, and the 
subjects ‚Äô participation in the study must be documented in the subjects ‚Äô medical record/CRF.  
 
6.[ADDRESS_1168836] udy procedure for fema les with childbearing 
potential (one at pre-procedure screening and one on the day of the procedure prior to the 
procedure if the pre-procedure screening an d procedure are not performed on the same 
day). 
The following pretreatment assessments will be performed: 
‚Ä¢ Standard 2D photographic images will be captured via the Canfield Scientific Inc, 
VISIA CA imaging system. The same standa rdized photography views (right, left, 
front facing) will be used throughout the study as documented in the image capture 
document developed for the study. 
‚Ä¢ Urine pregnancy test for females of ch ildbearing potential; any premenopausal 
female capable of becoming pregnant. (Excluded: Non-chil dbearing potential, i.e. 
post-menopause, bilateral tubal ligation, oophorectomy, hysterectomy) 
‚Ä¢ Abbreviated general physical exam includin g medical history, vital signs, collection 
of subject‚Äôs  demographic information, Glogau photodamage assessment, Fitzpatrick 
skin type, Fitzpatrick Wrinkle and Elastosis Scale. (Appendi xes A, B, C respectively) 
 
Medications the subject is taking upon entry into  the study should also be documented in the 
case report forms. Documentation should includ e medications that study subjects take on an 
elective basis in addition to prescribed medications.  
 
After confirming fulfillment of all inclusion and exclusion criteria, the subject will be 
scheduled to undergo a CLEAR + BRILLIANT TOUCH
¬Æ 1440-nm and 1927-nm combination 
wavelength treatment. 
 
Patient Pre-treatment instructions: 
Protocol [V01-CBT-401] Bausch Health Americas, Inc.
Page 20 of 49
Version 3.0 09/13/2021 CONFIDENTIALxSkin types IV-VI: Begin Hydr oquinone 8% QHS at discreti on of treating physician, 2-
[ADDRESS_1168837]¬Æcleanser.
xDo not apply any topi[INVESTIGATOR_841207].
xDo not wear jewelry.
xHair pulled back.
xBring a hat to wear that shields from the sun.
xBring on day of treatment the sponsor provided CeraVe¬Æmoisturizer and SPF to 
apply after treatment.
6.3   Study Procedure
During the study procedure, subjects will be treated with the CLEAR + BRILLIANT TOUCH¬£
diode laser device combination waveleng th 1440-nm and 1927-nm treatment. 
Perform pattern preview test prior to use of device.
1. First the face will be cleansed with alcohol, topi[INVESTIGATOR_841208] 7% 
Lidocaine/7% Tetracaine will be applied 30 minutes prior to treatment.
2. Prior to treatment, the anesthetic will be fully wiped off and then face is cleaned 
again with rubbing alcohol to ensure face is free of all moisture and water. Allow to dry.
3. Provide patient protective  eyewear. (Disposable or Non-disposable laser eye 
shields). Laser goggles for staff. With ap propriate protection range for the system 
laser wavelengths (1440 nm ¬± 20 nm and 1927 ¬± 20 nm) and optical density of 5 
or greater. 
4. Attach single-use treatment tip.
5. Pre-set for 3200 cm
2treatment area coverage or Time: 40 minutes.
6. Full face will be treated with 4 passes of the 1440-nm Original handpi[INVESTIGATOR_841209] I-VI, with two pas ses in the horizontal direction and two 
passes in the vertical direction (Fig A.) in each treatment zone (Fig B, C). 
(Adjustments may be made to lower setting for patient tolerance)
7. Full face will be treated with 4 passes of the 1927-nm Perm√©a on high setting for 
all skin types I-VI, with two passes in the horizontal direction and two passes in 
Fig. A
Fig. C
Fig. B
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 21 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL the vertical direction in each treatment zone. (Adjustments may be made to lower 
setting for patient tolerance)  
8. The total is a combined [ADDRESS_1168838]¬Æ moisturizer and SPF 30+ to be appl ied to entire face immediately after 
treatment. 
6.[ADDRESS_1168839]-Procedure Care  Guidelines listed below: 
 Post Care and Instructions: 
1. Wash face with CeraVe
¬Æ gentle cleansing product only. 
2. Do not use an abrasive cleanser or brush device to clean face. 
3. Apply CeraVe¬Æ moisturizer minimum twice a day wh ile skin is healing and then as 
needed. 
4. SPF 30+ daily. (approved by [CONTACT_1697]) 
Sun exposure before and during treatment  can increase the risk of unwanted 
pi[INVESTIGATOR_371]. After treatment the skin is more sensitive to the sun, which can 
increase the risk of unwanted pi[INVESTIGATOR_841210]. Post-tre atment individuals 
should plan to use a high SPF sunscree n on a regular basis whenever they are 
outside. Ideally, a dual UVA/UVB sunscree n should be applied containing both a 
physical sun block (either or both zinc oxide or titanium dioxide) with a sun protection 
factor of [ADDRESS_1168840] sunlight is av oided and to wear sun-protective clothing 
(i.e. a wide-brimmed hat) when possible. 
5. Schedule next appointment. 
6. Review and dispense the Subject home  diary for post treatment skin effects. 
7. For patients on the 8% hy droquinone therapy (Skin types IV -VI) hold this application 
while skin is healing, then restart QHS or as directed. 
 
Subjects will be asked to return to the study site for subsequent procedures and post treatment follow up. 
 
Post procedure Standard 2D images will be captured via the Canfield Scientific Inc, VISIA CA imaging system during the follow-up visits.  
6.[ADDRESS_1168841] demographic information, procedural data, adverse events, tr eatment observations 
and study required assessments will be documented on the case report forms (CRFs). 
Study subjects will complete satisfaction and modified global aesthetic improvement scale evaluations at the 3-month follow up. The Investigators will assess post treatment skin effects immediately post treatment, at follow up  visits (prolonged post treatment) and quartile 
improvement scores at one (1) month and thre e (3) months in comparison to baseline 
photography. Blinded Investigators will provide analysis of unmarked 2D photo sets via 
Canfield clinical system. Review ers will select the order of baseline and post treatment at 
one (1) month and three (3) months. Then ba sed on their selection assess photos for 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 22 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL percentage improvement in photoaging damage using the quartile improvement scale and 
score 0-4.   
 
6.5.1 Photography 
VISIA CA facial photography system and services will be provided by [CONTACT_841237], Canfield Scientific,  Inc. (Parsippany, NJ) to document 
treatment effect from baseline to follow up visits. The camera system standardizes 
the facial (front, left and right oblique) images captured and lighting modalities.     
All consenting subjects‚Äô study photograph s will be captured using the equipment, 
supplies, and guidelines provided by [CONTACT_841238].   
Images will be captured, viewed, and uploaded using Canfield Clinical Services 
website which automatically checks, sums , encrypts, packages, and transfers the 
data to a secure, validated and complian t web server hosted by [CONTACT_73957]. Only 
approved individuals by [CONTACT_841239].  
Detailed instructions for all aspects of the photography procedures will be supplied 
separately in the investigator user manual to be provided by [CONTACT_841240].  Images will 
be utilized for study research purposes (add other purposes, analysis if 
applicable).  
6.5.[ADDRESS_1168842] three (3) punch biopsies taken by [CONTACT_841241] 
(area of photodamage). Location of biopsi es will be pre-auricular, at temporal 
hairline, or the forearm. Pre- and post-tre atment biopsies must be taken from the 
same general location for each patient.  
 
x The first biopsy will be collected at Scre ening/Baseline visit (pre-Treatment #1) 
The first treatment will be subsequently scheduled at the discretion of the 
principal investigator [INVESTIGATOR_841211]. 
x The second biopsy will be collected at [ADDRESS_1168843] biopsy will be collected at 3-month follow up (3-months post final 
treatment, Treatment #4).  
6.6   Final Study Visit 
 
Three-month 2D follow-up photographs will be ta ken captured via the Canfield Scientific Inc, 
VISIA CA imaging system.  
Subjects will complete satisfaction surveys and GAIS overall improvement scores. 
 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 23 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL Investigators will complete Quartile Improvemen t Scales comparing baseline photography to 
3 months photography. 
 
6.7   Study Completion 
 
The Sponsor or its representative will notify the Investigator and/or the IRB, as applicable, to inform them when the study is complete. The study will be considered complete when all 
enrolled subjects either have completed study visits through Visit 7 (3-month follow up) or 
have been discontinued from the study prior to Visit 7 for any reason. 
 
6.8   Schedule of Events Table 
 
Schedule of Events 
 VISIT 1 VISIT 2 VISIT 2a VISIT 3 VISIT 4 VISIT 5 VISIT 6 VISIT 7 
PROCEDURES  Screening 
Visit  
(Day -30 to 
0) Treatment 
#1 
(Baseline) Day 14 
Biopsy  
([ADDRESS_1168844] 
treatment 
#1, +/- 7 
days)  Treatment #2 
(1-month post 
treatment #1, 
+/- 7 days)  Treatment #3 
(1-month post 
treatment #2, 
+/- 7 days)  Treatment #4 
(1-month post 
treatment #3, 
+/- 7 days)  1-Month 
F/U  
([ADDRESS_1168845] final 
treatment, +/
- 7 days)  3-Month 
F/U 
([ADDRESS_1168846] final 
treatment, 
+/- 7 days)  
Informed Consent/Photo 
Release X        
Demographics X        
Medical History X X       
Vital Signs X        
Concomitant Medications X X  X X X X X 
Inclusion/Exclusion 
Criteria X X       
Previous Therapi[INVESTIGATOR_014] X X       
Urine Pregnancy Test  X X       
2D Standard Photography  X  X X X X X 
Investigator Intake 
Assessments  X X       
Punch Biopsy  X  X     X 
Laser Treatment  X  X X X   
VAS Visual Analog Scale  X  X X X   
Side Effects Evaluation  X  X X X X X 
Adverse Events Review X X  X X X X X 
Investigator Quartile 
Improvement Evaluation       X X 
Prolonged Treatment 
Effects       X X 
Subject GAIS        X 
Subject Diarya  X  X X X   
Subject Satisfaction        X 
End of Treatment(s)      X   
End of Study        X 
a. Subject‚Äôs will log post -treatment skin responses, side effects (e.g., erythema, edema) using a scale of 0 to 3 (none to marked) after each 
treatment for seven (7) days in the subject diary. 
 
 
 
Protocol [V01-CBT-401] Bausch Health Americas, Inc.
Page 24 of 49
Version 3.0 09/13/[ADDRESS_1168847] is to be examined to determine if  they qualify for entry into the study. This initial 
examination will include:
xObtain written Informed Cons ent and photographic release
xReview Inclusion/Exclusion Criteria 
xRecord Medical History/Meds/Vital Signs
xUrine Pregnancy Test (if applicable): only one is necessary prior to start of treatments.
xDispense CeraVe¬Æ Products
xSkin types IV-VI: Begin Hydroquinone 8% QHS at discretion of treating physician 2-[ADDRESS_1168848] treatment. Hold while skin is healing, then restart QHS or as directed.
xInvestigator Assessments: Glogau Photodamage, Fitzpatrick Skin Type and Wrinkle & Elastosis
Scale
xBiopsy #1 of five patients (baseline)Note: Screening and Baseline visits may occur on the same day for non biopsy patients.
This treatment visit will include:
xPhotographs prior to treatment: wait at least [ADDRESS_1168849] (if applicable): only one is necessary prior to start of treatments.
xLaser treatment to the face
xVAS Scale
xPost Treatment Skin effects (provider)
xReview for Adverse Events (provider)
xSubject Diary post treatment (7 days) given to patient.
xBiopsy #2 of selected five patients
This treatment visit will include:
xPrior to treatment: wait at least [ADDRESS_1168850] Treatment Skin effects (provider)
xReview for Adverse Events (provider)
xSubject Diary post treatment (7 days) given to patient
This treatment visit will include:
xPrior to treatment: wait at least [ADDRESS_1168851] Treatment Skin effects (provider)
xReview for Adverse Events (provider)
xSubject Diary post treatment (7 days) given to patient
This treatment visit will include:
xPrior to treatment: wait at least [ADDRESS_1168852] photography via Canfield VISIA CA 
Screening
Baseline/Treatment #1   (Screeni ng/Baseline may be on same day)
Biopsy Patients Only ([ADDRESS_1168853] treatment #1, +/- 7 days )
Treatment #2       (one-month post treatment #1, +/- 7 days)
Treatment #3      (one -mon th post treatment #2, +/- 7 days)
Treatment #4   (one-month post treatment #3,+/- 7 days,)

Protocol [V01-CBT-401] Bausch Health Americas, Inc.
Page 25 of 49
Version 3.0 09/13/[ADDRESS_1168854] Treatment Skin effects (provider)
xReview for Adverse Events (provider)
xSubject Diary post treatment (7 days) given to patient
This follow-up examination will include:
xPhotography: wait at least [ADDRESS_1168855] Treatment Skin effects
xReview for Adverse Events
xInvestigator Quartile Percent Improvement Evaluation
This follow-up examination will include:
xPhotography: wait at least [ADDRESS_1168856] GAIS and satisfaction
xInvestigator Quartile Percent Improvement Evaluation
xBiopsy #[ADDRESS_1168857] 2D Photography
Two-dimensional (2D) facial photographic images will be captured by [CONTACT_841242], 
Inc. VISIA CA imaging system.
xThe camera system standardizes the facial  (front, left and right oblique) images 
captured and lighting modalities.
xAll makeup should be removed, hair pulled back in consistent manner and 
behind the ears, all jewelry removed.
xPatients will be notified in their informed consent about the collection and use of 
their photographs for research purposes  which may be used for scientific, 
educational presentations or publications.
The data will be comparing baseline photos to 1- and 3-months post treatment for results.
7.2   Investigator Evaluations Quartile Improvement Score
Treating Investigators will compare: 
1. Baseline photographs to one-month post treatment. 2. Baseline photographs to three-months post treatment.
A Quartile Improvement Scale will be used to individually score each category: (a) fine 
wrinkles, (b) skin texture, (c) dyschromia/pi[INVESTIGATOR_178718] t, (d) skin radiance, (e) pore size and (f) 
overall appearance.
Follow-Up Visit  (one-month po st treatment #4, +/- 7 days)
Follow-Up Visit (three months post treatment #4, +/- 7 days)

Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 26 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL  
 
 
   
 
 
7.3   Punch Biopsies 
     
Up to five (5) subjects will be consented to provide skin biopsies. Each subject will provide 
up to three (3) punch biopsies. 2 mm punch biopsies will be ta ken from the location on the 
face in an area of photoaging at discretion of  investigating physician either pre-auricular or 
at temple hairline. If face location is unatta inable the forearm (exposed to photoaging) may 
be used as an altern ate biopsy location and will receive the combined laser treatment in 
addition to receiving a facial treatment. Pre- and post-treatment biopsi es must be taken from 
the same general locati on for each patient. 
Biopsies will be obtained us ing standard sterile techniqu e after an intradermal local 
anesthesia, closed with suture (at the discreti on of the Sub-Investigator/Study Physician), 
and treated with topi[INVESTIGATOR_841212]. Subjects‚Äô skin may 
be marked with a surgical marker to use as re ference. Complete anesthesia of the biopsy 
site will be confirmed prior to the punch being inserted.  
The biopsies will be imme diately transferred into 10% formal in solution and stored at room 
temperature.  Collected biopsy samples will be sent to Propath for biopsy sample analysis. 
IHC staining for Procolla gen I, elastin, CD31, lymphocyte count, Masson‚Äôs  trichrome, GAG 
(Colloidal/Fe), and H&E, with images. 15 samples total will be collected (5 sets at baseline, 
day 14 and final visit). 
The biopsy sample manifest will be sent to Propath and will contai n the subject number, 
product information, total number of biopsies collected, and any other relevant information 
needed to identify th e samples post-analysis.  
7.4   Visual Analog Scale (VAS) 
 
The study subjects will be asked to complete an  eleven point visual analog scale (VAS, 0-
10) for the level of pain and discomfort associ ated with the study procedure to be completed 
by [CONTACT_841243] [ADDRESS_1168858].  Investigator Quartile Improvement Score 
Rating Percentage (%) Score 
No Improvement 0% 0 
Minor/Mild Improvement 1%-25% 1 
Moderate Improvement 26%-50% 2 
Marked Improvement 51%-75% 3 
Very Significant Improvement 76%-100% 4 

Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 27 of 49  
Version 3.0 09/13/[ADDRESS_1168859] Satisfaction 
 
Using a five (5) point Likert scale the study subjects will be asked to complete a satisfaction 
survey to rate their overall treatment resu lts at the three-month follow-up visit.  
 
Overall how would you rate your satisfaction with the 
treatment results?  Very Dissatisfied [ADDRESS_1168860] Modified Global Aesthetic Improvement Score 
 The Modified Glob al Aesthetic Improvement Scale (GAI S) is a subjective rating of 
improvement of treatment results compared to pre-treatment. The subjects will grade the 
overall improvement of the appearance of the treatment areas. The subject will compare their appearance at  three months against a phot ograph taken at baseline. 
7.7   Independent Photographic Assessments  
 
Two experienced, blinded photographic review ers will compare 2D photographs via Canfield 
Scientific, Inc VISIA data access system:  
1. The reviewer will select between [ADDRESS_1168861] treatment they will rate improvement.  
A Quartile Improvement Scale wi ll be used to individually sco re each category: (a) fine 
wrinkles, (b) skin texture, (c) dyschromia/pi[INVESTIGATOR_2517], (d) skin radiance, (e) pore size and (f) 
overall appearance.   
 
 SUBJECT MODIFIED GLOBAL AESTHETIC IMPROVEMENT SCALE 
Comparing baseline photograph to three-months photograph.                    Rating 
 
How do you rate your overall appearance compared to before 
treatment?   Very Much Improved 
 Much Improved 
 Improved 
 No Change 
 Worse 
 Much Worse 
 Very Much Worse 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 28 of 49  
Version 3.0 09/13/[ADDRESS_1168862]-treatment skin responses, side effects (e.g., erythema, edema) will be scored 
by [CONTACT_30967], as appropriate, using a scale of 0 to 3 (none to marked), 
immediately after treatmen t, for each treatment. 
x Side effects (prolonged erythema, edem a, skin darkening or lightening in the 
treatment area, scarring, dryness/flakiness, blistering) will be scored, using a scale of 
0 to 3 (none to marked), by [CONTACT_841244], and at all follow-up visits. 
x Subject‚Äôs will log post -treatment skin responses, side effects (e.g., erythema, edema) 
using a scale of 0 to 3 (none to marked), after each treatment for seven (7) days in 
the patient diary. 
x In addition, study subjects will be instructed  to report all complications experienced 
post study procedure to the site personne l as soon as they occur/are observed.  
x It is the Investigator‚Äôs responsibility to determine seriousness, severity, and 
relatedness of the Adverse Event to th e device and the procedure using the 
definitions below.  
 
8.1.1   Definition of Serious Adverse Events (SAE) 
 
Serious Adverse Event (SAE) is an adverse event that: 
‚Ä¢ Led to a death or 
‚Ä¢ Led to a serious deterioration in the health of a subject that: 
¬É Resulted in a life-thre atening illness or injury, 
¬É Resulted in a permanent impairment of  a body structure or body function,  
¬É Required inpatient hospi[INVESTIGATOR_5186] n or prolongation  of existing 
hospi[INVESTIGATOR_059],  
¬É Resulted in medical or surgical interv ention to prevent impairment to body 
structure or a body function, or  
¬É Lead to fetal distress, fetal death or congenital abnormality or birth defect. 
 Blinded Investigator Quartile Improvement Score 
Rating Percentage (%) Score 
No Improvement 0% 0 
Minor/Mild Improvement 1%-25% 1 
Moderate Improvement 26%-50% 2 
Marked Improvement 51%-75% 3 
Very Significant Improvement 76%-100% 4 
Protocol [V01-CBT-401] Bausch Health Americas, Inc.
 
Page 29 of 49  
Version 3.0 09/13/[ADDRESS_1168863] be report ed to the Sponsor within 24 hours of 
knowledge of the event. IRB reporting requirements may also apply to SAEs.
8.1.2   Definition of Adverse Events (AE)
An adverse event (AE) is any untoward or unfavorable medical occurrence in a 
human subject, including any abnormal sign (for example, abnormal physical exam 
or laboratory finding), symptom or di sease temporarily associated with the 
subject ‚Äôs participation in research whether or not considered related to the 
subject ‚Äôs participation in the research period.
A pre-existing condition (one that is present at the start of the study) will be 
recorded as an AE only if the frequency, intensity or the character of the condition 
worsens during the study period.
8.1.[ADDRESS_1168864] (UADEs)
Any serious adverse effect on  health or safety or any life-threatening problem or 
death caused by, or associated with, a device , if that effect, problem, or death, was 
not previously identified in a nature, severity, or degree of incidence in the investigational plan or application (includi ng a supplementary plan or application), 
or any other unantici pated serious problem associated with a device that relates to 
the rights, safety, or welfare of subjects
In addition, any UADEs will be reported to  the Sponsor and the reviewing IRB as 
soon as possible, but no later than with in 24 hours of knowledge of the event.
All adverse events, anticipated or unanticipated, will be monitored until they are 
adequately resolved or explained.
8.1.4   Definition of Device Malfunction
Malfunction means the failure of a device to  meet its performance specifications or 
otherwise perform as intended. Performance specifications include all claims made 
in the labeling for the device. The intende d performance of a de vice refers to the 
intended use for which the device is labele d or marketed, as defined in 21 CFR ¬ß
801.4.
8.2   Adverse Event / Device Malfunction Reporting
In the case of an AE (Serious and Significan t Non-Serious) or UADE the Investigator must:
Report the AE or UADE to the Medical Monitor within 24 ho urs of knowledge of the event 
using the Sponsor -provided form (SAE/U ADE reporting form , Appendix D ) by [CONTACT_841245] [V01-CBT-401] Bausch Health Americas, Inc.
 
Page 30 of 49  
Version 3.0 09/13/2021 CONFIDENTIALThe Medical Monitor will email/fax a copy of the form immediately (within 24 hours) for 
SAEs /UADEs only to upon 
receipt.
In the case of Device Malfunctions, the Investigator must:
Report the Device Malfunction within 24 hours using the Sponsor -provided form (Device 
Malfunction reporting form, Append ix E) by [CONTACT_841246], Investigators or other study staff from first exposure to 
the study product through last study follow-up vi sit will be recorded. If a device-related AE,
SAE, unanticipated serious device related effect or device malfunction is ongoing at the final 
study visit, the subject will be followed until resolution, until the condition stabilizes, until the 
event is otherwise explained, or the subject is  lost to follow-up. The Investigator should 
make every effort to ensure the follow-up incl udes any supplemental investigations as may 
be indicated to elucidate, as completely practica l, the nature and or causality of the AE or 
SAE. This may include unscheduled fo llow up visits for AE assessment. 
Study subjects will be instructed to report all adverse events to the clinical study staff and
information will be collected throughout the stud y and recorded on the case report forms and 
reported to Solta Medical Customer Service.
8.3   Classification of Adverse Events
The severity of adverse events will be categorized using the following criteria:
‚Ä¢Mild: easily tolerated by [CONTACT_841247]. Th ese events generally do not require 
treatment.
‚Ä¢Moderate: sufficiently discomforting to interf ere with normal everyday activities.
These events are usually relieved by [CONTACT_14212]. 
‚Ä¢Severe : prevents normal everyday activities these events may require systemic
drug therapy or other medical treatment.
8.4   Relationship to the study device and/or procedure
The causality assessment is a determination of  the relationship betw een the investigational 
device or surgical procedure and the occurrence of an AE/SAE. 
The possibility of a link betwee n the study device or surgical procedure and an AE will take 
into consideration (as a minimum) the following criteria:
xExistence of a temporal link between the event and administration of the study 
device.
xEvent is not explained by [CONTACT_841248], measure or environmental factor.
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 31 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL For this study, causality will be defined as: 
 
x Related:   There is at least a reasonable possibility that the AE/SAE is related to 
the study device or surgical procedure. Reasonable possibility means that there 
is evidence to suggest a causal relati onship or association between the study 
device and the AE.  Also re ferred to as an ADE. 
x Unrelated:   There is little or no reasonable  possibility that the AE/SAE is related 
to the study device or surgical procedu re.  This assessment implies that the 
AE/SAE has no evidence to suggest either a causal relationship or association to 
the study device or surgical procedure and  more likely or certain an alternative 
etiology exists. 
 
8.5   Termination of Study Rules for Safety 
 
The Sponsor and/or Investigator may recommend termination or modification of the study if 
there is an occurrence of any device or tr eatment related Serious Adverse Event using the 
following clinical protocol definitions of Se rious Adverse Event in section 8.1.1 of this 
protocol. In addition, termination, or modi fication may be reco mmended for any other 
perceived safety concern based on clinical judgment, including but not limited to a higher than anticipated rate for any component of th e safety measures, device failures result 
resulting in Adverse Events or unexpected SAEs.  
9.   RISKS AND BENEFITS 
9.1   Benefits 
 
A possible benefit of using the  CLEAR + BRILLIANT TOUCH¬£ diode laser technology in a 
combination wavelength same session treatment,  over a series of four treatments, is an 
enhanced improvement in the tone, texture, radiance, fine lines, pore size and overall 
appearance of the skin compared  to no treatment at all. 
 
9.[ADDRESS_1168865] shown that  CLEAR + BRILLIANT diode laser treatments have a 
demonstrated safety profile. There is a very low incidence of side effects and 
complications associated with treatment. Risks and discomforts for subjects who 
participate in this study are the sa me as for subjects  undergoing any 
dermatological laser treatment. Eye injury due to use of the laser system is a risk to the subject and the operator. Appropriate ey e protection will be used to minimize 
that risk. Mild to moderate local pain is  a typi[INVESTIGATOR_841213]. 
Topi[INVESTIGATOR_841214]. Eye injuries may result from numbing cream getting into the eyes. Eyes will be covered with protective 
eyewear during treatment and should remain closed during the treatment. 
 
 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 32 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL Expected Responses:  
‚Ä¢ Erythema (Redness)  
‚Ä¢ Edema (Swelling) . 
‚Ä¢ Itching/Dryness  
‚Ä¢ Increased Skin Sensitivity  
‚Ä¢ Pain or Discomfort  
‚Ä¢ Pi[INVESTIGATOR_841215]/Petechia  
 
9.2.[ADDRESS_1168866]-inflammatory hypopi[INVESTIGATOR_841216] -pi[INVESTIGATOR_841217] + BRILLIANT TOUCH¬£ treatment. Following 
appropriate instructions for sun protection will lower the risk for pi[INVESTIGATOR_16576]. 
Infection A risk of infection exists whenever the skin is wounded.  The possibility 
for infection exists even with non -ablative fractional laser devices such as 
the CLEAR + BRILLIANT TOUCH¬£ System. An infection should be 
treated appropriately with topi[INVESTIGATOR_199]/or systemic medications. 
Prolonged Redness Mild-moderate transient erythema is an  expected response with any laser 
treatment.  However, if erythema is severe or persists significantly longer 
than expected, re -treatment should be avoided until the condition 
resolves. Reaction may vary on a person-to-person basis. 
Scarring The possibility for scarring exists with  any laser treatment, even with non-
ablative laser devices suc h as CLEAR + BRILLIANT TOUCH¬£ System . 
Local scarring may occur directly from laser exposure if treatment 
procedures are not followed properly, or from infection or physical 
irritation such as pi[INVESTIGATOR_841218]. 
Delayed Wound 
Healing/Skin Textural 
Change s Following any laser trea tment, re-epi[INVESTIGATOR_841219]‚Äôs physiology (i.e. poor wound healing 
ability, or post -treatment care). This may re sult in undesirable textural 
changes. 
Temporary Bruising Temporary bruising may develop over the treated areas and typi[INVESTIGATOR_841220]. 
 
9.2.[ADDRESS_1168867] a small scar. The 
scar may be permanent. 
 
 
 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 33 of 49  
Version 3.0 09/13/[ADDRESS_1168868] training and 
are experienced in (1) performing energy ba sed and laser procedures and (2) following 
study treatment procedures. In addition, risks are mitigated by [CONTACT_687098]. The st udy also includes evalua tion of study subject 
satisfaction with this procedure. Given the anticipated acceptable risk, the risk benefit 
assessment of the use of the CLEAR + BRILLIANT TOUCH¬£ diode laser device to improve the 
appearance of photoaged skin appe ars to offer a substantial clinical benefit at a reasonable 
risk.   Further discussion of risks of the of the CL EAR + BRILLIANT TOUCH¬Æ System can also be 
found and should be accessed in the CLEAR + BRILLIANT TOUCH¬Æ Laser System 
User Manual provided by [CONTACT_1034]. 
10.   STATISTICS 
10.1   Statistical Analysis Populations and Demographics 
 
The intent-to-treat (ITT) populati on will be the primary population for all statistical analyses. 
The ITT population will include al l subjects who received treatment, participated in at least [ADDRESS_1168869](s) excl uded from an analysis population 
will be documented in a note to file  and included in the study report. 
Demographic data and baseline characteristics, in cluding age, gender, ethnicity, Fitzpatrick 
skin type, Glogau rating, and Fitzpatrick wrinkle & elastosis scale rating, will be summarized 
according to the analysis population for all su bjects. For continuous variables, descriptive 
statistics including number of subjects (N ), mean, median, stan dard deviation (SD), 
minimum (MIN) and maximum (MAX) values will be presented. For categorical variables, the count and percentage of each category will be provided. The denominator for all percentages will be the number of subjects with non-missing data at the given visit for each 
respective study treatment, unless otherwise indicated. 
The sample size determination of this stud y is based on the Sponsor‚Äôs recommendations  to 
quantify the effectiveness and safety of the CLEAR + BRILLIANT TOUCH
¬£ diode laser 
1440-nm and 1927-nm Laser in the context of this study. Power calculations were 
performed based on estimates for expected  mean change and variance in overall 
appearance at 3 months as rated by [CONTACT_841249] 12-133-CBP-F ( ‚ÄòEvaluation of the skin after treatment with the Clear + Brilliant 
1927-nm wavelength laser by [CONTACT_841250]-CA Imaging System ‚Äô). The power 
calculations demonstrated a sample size of 25 ha s greater than 95% power to reject the null 
hypothesis (change from baseline=0) for the primary efficacy endpoint. Thus, up to 30 
subjects will be enrolled to account for potential drop-out. 
 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 34 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL 10.2   Statistical Analysis Plan (SAP) 
 
10.2.1 Descriptive Statistical Summary 
A descriptive statistical summary will be provided for Investigator Quartile Improvement Score (IQIS, 0-4), tolerability parameters , VAS scores, and biopsy parameters. The 
descriptive statistical summary includes the N, mean, median, SD, MIN, and MAX of 
scores/values at all applicable time points.  
 Counts and percentages will be provided for Investigator Quartile Improvement Score (rating), SAE parameters, tolerability parameters , VAS (in category), and individual response 
data (GAIS and subject satisfaction). 
 
10.2.2 Additional Analysis 
Additional analysis will be provided as following: 
For IQIS (0-4), the mean score will be compared to a constant value of [ADDRESS_1168870] satisfaction data, a binomial (sign) test will be performed to test if the proportion of the combined designated favora ble responses (Very Mu ch Improved, Much 
Improved, and Improved for GAIS; Very Satisfie d and Satisfied for subj ect satisfaction) is 
equal to the combined designated unfavorable responses. 
 
Statistical Analysis Plan Table 
 
Evaluation Change from baseline Notes/Interpretation 
Investigator 
Quartile 
Improvement 
Score  The mean score (0-4) will 
be compared to the 
constant 0, using Wilcoxon 
signed rank test  Significantly greater than 0 
indicates improvement. 
SAEs NA Zero or low number of SAEs is 
favorable 
Tolerability parameters NA Lower score indicates better tolerability 
VAS  NA Lower score indicates better 
tolerability  
Biopsy parameters NA Descriptive statistics only 
Individual 
response data 
(GAIS and 
satisfaction) NA A binomial test (sign test) P value 
will be provided. A higher 
percentage of combined favorable 
responses with a significant P 
value indicates positive subject 
perceptions of the test material. 
Blinded 
Investigators The mean score (0-4) will 
be compared to the 
constant 0, using Wilcoxson 
signed rank test  Significantly greater than 0 indicates 
improvement.  
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 35 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL  
All statistical tests will be 2-sided at significance level alpha=0.05 unless specified 
otherwise. P values will be reported to 3 decimal places (0.000).  
No multiple testing corrections will be consid ered in the study. Statistical analyses are 
performed using SAS software version 9.4 (SAS St atistical Institute). The statistical results 
will be sent to the Sponsor along with raw data in a Microsoft Excel document at completion 
of the study. 
 
10.2.3 Minimiza tion of Bias and Potent ial Confounding Factors 
Blinded investigator phot o evaluation is intend ed to minimize bias. 
11.   SOURCE DOCUMENTS AND ACCESS TO DATA/DOCUMENTS 
 
The PI [INVESTIGATOR_841221].  
 
This clinical investigation will pe rmit the investigator to proceed with ‚Äúdata entry‚Äù directly onto 
the case report forms (CRFs).  In this case, the CRFs will also serve as the source record 
for each participating subject.  A copy of the CRFs will be collected by [CONTACT_841251]‚Äôs Inc. 
for data analysis.   
12.   QUALITY ASSURANCE AND QUALITY CONTROLS 
 
Each investigational site will undergo a detailed training that highlights the key tenets for 
maintaining quality management. The investig ational sites will be instructed regarding 
protocol compliance, use of CRFs, and proper  treatment administration. The investigator 
must assure that subject confidentiality will be maintained and that partic ipant identities shall 
be protected from unauthorized parties. 
 
12.[ADDRESS_1168871] be al lowed to visit the study site location to 
assess the data, quality, and study integrity. 
 
Prior to the start of the study, member(s) of the Sponsor (or designees) will review the 
protocol, CRF, regulatory obligations, and othe r material or equipment relevant to the 
conduct of the study with the Investigator  and relevant stud y site personnel. 
 
Monitoring visits and telephone consultations will occur as necessary, as per the monitoring plan, during the course of the investigation. During the course of the study, all data will be 100% source document-verified by [CONTACT_841252]. All subject source 
documents must be made av ailable to the monitors. 
 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 36 of 49  
Version 3.0 09/13/[ADDRESS_1168872] 
 
The investigator will ensure that this study is conducted in full conformity with the principles 
set forth in the Declaration of Helsinki, EN IS O [ZIP_CODE]:2020 Clinical Investigation of Medical 
Devices for Human Subjects ‚Äì Good Clinical Practices, [ADDRESS_1168873] 
 
Before commencing with and enrolling voluntee rs for this proposed study, the appropriate 
documents (including the Protocol, Investiga tor‚Äôs Brochure, Informed Consent Form, 
information sheets, CRF‚Äôs and advertisements) will be submitted to the IRB. The investigator 
will be responsible for obtaining IRB approval fo r the study. Protocol deviations will also be 
reported to the IRB according to the policy of the board. Protocol amendments will be reviewed and approved by [CONTACT_841253]. 
 
The investigators will inform the IRB: 
‚Ä¢ All subsequent protocol amendments, in formed consent changes or revisions of 
other documents originally submitted for review 
‚Ä¢ Serious and/or unexpected adverse even ts occurring during the study, where 
required 
‚Ä¢ New information that may affect adversely the safety of the participants or the 
conduct of the study 
‚Ä¢ An annual update and/or request for re-approval, where required barring 
unforeseen circumstances, this study is anticipated to be completed within 9-10 
months.  
‚Ä¢ When the study has been completed. 
 
13.3   Informed Consent Process 
 
Informed consent is a process that is initiated prior to the individual‚Äôs agreeing to participate in the study and continues throughout the in dividual‚Äôs study participation. Extensive 
discussion of risks and possible bene fits of this therapy will be provided to the subjects and 
their families. Consent forms describing in detail the study interventions/products, study 
procedures, and risks are given to the subj ect and written documentation of informed 
consent is required prior to starting interven tion/administering study product. Consent forms 
will be IRB-approved, and the subject will be asked to read and review the document. Upon 
reviewing the document, the investigator will ex plain the research study to the subject and 
answer any questions that may arise. The subject will sign the informed consent document (ICD) prior to any procedures being done spec ifically for the study. The subjects should 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 37 of 49  
Version 3.0 09/13/[ADDRESS_1168874] by [CONTACT_3486], their staff, and 
the sponsor(s) and their agents. This confid entiality is extended to cover all recorded 
information during the clinical study. The clinic al investigation will be registered in a publicly 
available database. In addition, the results of the study will be published in a publicly 
available database.  
 
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No information concerning the study, or the data, will be released to any unauthorized third party without prior written approval of the sponsor.  
 
The study monitors or other authorized representatives of the sponsor may inspect all 
documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects 
in this study.  
 Subjects‚Äô identities will be kept confid ential by [CONTACT_148787] a s ubject ID upon 
acceptance into the study. The subject ID will comprise the site ID and a three-digit number 
that will be based upon the subject‚Äôs order of entry into the study. The study Sponsor will not 
receive any additional identify ing information about a subject and will therefore have no way 
of linking a subject ID to a subj ect and his or her results.   
 
   13.4.[ADDRESS_1168875] human biopsy samples per local and federal 
guidelines after processing of samples. 
 
 
 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 38 of 49  
Version 3.0 09/13/[ADDRESS_1168876]. An original Financial Disclosure Form (FDF) must be 
completed, signed and dated by [CONTACT_458] (PI) and any sub-investigators. All 
FDFs will be collected by [CONTACT_841254]. 
A copy of all FDFs will be retained in the Investigator Site Binder.  
 
13.6  Finance 
 
The study is financed by [CONTACT_1034]. The Sp onsor carries insurance that covers clinical 
trials, which is filed under the company‚Äôs Master Policy for clinical trials conducted within the 
U.S. 
14.   DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_1645] 
14.[ADDRESS_1168877] maintain complete and 
accurate documentation for the study. 
 Data management and oversight is the respon sibility of the Sponsor and SGS Stephens Inc. 
Responsibilities include but are not limited to the following  
‚Ä¢ Clinical strategy and oversight  
‚Ä¢ Clinical study operations  
‚Ä¢ File management and study documentation  
‚Ä¢ Site initiation visit and study closeout visits  
‚Ä¢ Clinical quality assurance  
‚Ä¢ Statistical support and programming  
‚Ä¢ Data management including database development and programming and electronic 
data capture programming training and management  
 
Additionally, management and ov ersight of photographic imaging is the responsibility of the 
Sponsor and SGS Stephens Inc (Clinical Research Organization). 
 
Responsibilities may be delegat ed to applicable vendors.  
 Data will be recorded on case report form s (CRFs). A CRF is required and should be 
completed for each included subject. 
 
A single-entry method will be used to enter the data captured on paper records into an electronic data capture (EDC) system. Nume rical data described in Section 7 will be 
recorded using the SGS Stephens EDC system, which documents the identity of the 
evaluator/technician as we ll as the time and date of all entr ies, or all corrected entries. The 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 39 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL SGS Stephens EDC is a computerized system desi gned for the collection of clinical data in 
electronic format. The 3 major aspects of EDC ar e a graphical user interface for data entry, 
a validation component to chec k for user data, and a reporting tool for analysis of the 
collected data. The entries will be compared to the paper CRFs with 100% source document 
verification by [CONTACT_841255], and any mi ssing data and/or 
inconsistencies will be identified and corrected. 
 It is the investigator‚Äôs responsibility to ens ure completion, review and approve all CRFs. 
CRFs must be signed by [CONTACT_841256]. These signatures 
serve to attest that the information contained on the CRFs are true. At all times, the 
investigator has final personal responsibility for the accuracy and authenticity of all clinical 
and laboratory data entered on the CRFs. 
 
Photographic images will be captured utilizing the Canfield Scientific, Inc. VISIA CA Imaging 
system.   
14.2   Study Records Retention 
 
To enable evalua tions and/or audits from regulatory authorities or the Sponsor, the 
investigator agrees to keep records including the identity of all participating subjects 
(sufficient information to link records, e.g., CRFs and hospi[INVESTIGATOR_1097]), all original signed 
informed consent forms, copi[INVESTIGATOR_4600], serious adverse event forms, source documents, and detailed records of treatment disposition.  The records should be retained 
by [CONTACT_841257] [ADDRESS_1168878] obtain Sponsor's written permission before disposing of any records, even if retention requirements have been met. 
 
14.[ADDRESS_1168879] of the study as described in 
this protocol, Good Clinical Practice (GCP), or the investigational device Manual of 
operations.   
 
The non-conformance may be either initiated by [CONTACT_423], the investigator, or the study 
staff. Protocol deviations must  be tracked and reported to the Sponsor in a timely manner, 
and corrective action implemented and document ed. Protocol deviations affecting the safety 
of the subject or the integrity of the study must  be reported by [CONTACT_841258]. Reporting of all other protocol deviat ions must adhere to the requirements of the 
governing IRB. 
 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 40 of 49  
Version 3.0 09/13/[ADDRESS_1168880] to study subjects without prior 
IRB or Sponsor approval. As soon as possibl e after such an occurrence, the implemented 
deviation or change, the reasons for it, and an y proposed protocol amendment(s) should be 
submitted to the IRB for review and approval, to the Sponsor for agreement, and to the 
regulatory authorities, if required. 
 
 
14.4   Publications and Data Sharing 
 The publication policy will be in accordance with the investigator agreement with each 
principal investigator [INVESTIGATOR_825199]. No information on individual subjects will be 
revealed in any publicatio ns or presentations.  
 The SGS Stephens group will compose the study report for the Company Sponsor. 
 
 
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 41 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL 15. LITERATURE REFERENCES 
 
1. Ayer, J., Griffiths, C. (2019). Photoaging in Caucasians, Cutaneous Photoaging; pp. 1-30. 
Doi: 10.1039/9781788015981-[ZIP_CODE] 
2. Bauer, J., Alabdulrazzaq, H., Bae, YS. (2015) . Evaluation of a low energy, low density, non-
ablative fractional 1927nm wavelength  laser for facial skin resurfacing. Journal of Drugs in 
Dermatology, 14 (11). 1262-1267. 
3. Borges, J., Manela-Azulay, M., Cuzzi, T. (2016). Photoaging and the clinical utility of 
fractional laser. Clinical, Cosmetic, and Investigational Dermatology, (9), 107-114. 
4. Manstein D, Herron GS, Sink RK, Tanner H,  Anderson RR. Fractional photothermolysis: a 
new concept for cutaneous remodeling using micr oscopic patterns of thermal injury. Lasers 
Surg Med 34(5): 426-38. (2004). 
5. Narukar, V., Alster, T., Bernstein, E., Lin, T., Loncaric, A., (2018). Safety and efficacy of a 
1550 nm/1927 nm dual-wavelength laser for the treatment of photodamaged skin.  Journal of 
Drugs in Dermatology (17) 1, 41-46. 
6. Rahman, Z., Alam, M., Dover, J.S. (2006). Fractional laser treatment for pi[INVESTIGATOR_841222]. Skin Therapy Letter (11) 9.  
7. Rittie, L., Fisher, G. (2015). Natural and sun-induced aging of human skin. Cold Spring 
Harbor Perspective Medicine. Cold Spri ng Harbor Laboratory Press. Doi: 
10.1101/cshperspect.a015370 
8. Solta Medical, Inc. (2020) CLEAR + BRILLIANT TOUCH¬ì laser system user manual. 
Bothell, WA; Solta Medical Inc. 
9. Solta Medical, Inc. (2013) CLEAR + BRILLIANT¬ì laser system operator manual. Bothell, 
WA; Solta Medical, Inc. 
 
 
 
  
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 42 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL Appendix Section  
 
Appendix A: Glogau Photodamage Scale 
 
Appendix B: Fitzpatrick Wrinkle and Elastosis Scale 
 
Fitzpatrick Wrinkle and Elastosis Scale 
Class Wrinkling Score Degree of Elastosis 
I Fine wrinkles 1-3 Mild:  fine texture changes with subtly 
accentuated skin lines  
II Fine to moderate depth wrinkles, 
moderate number of lines  4-6 Moderate:  distinct popular elastosis 
(individual papules with yellow 
translucency under direct lighting) and dyschromia.
 
III Fine to deep wrinkles, numerous 
lines. With or without redundant 
skin folds  7-9 Severe:  multipapular and confluent 
elastosis (thickened, yellow and pallid) 
approaching or consistent with cutis 
rhomboidalis.  
 
 Glogau Photodamage Scale 
Group 
Classification Typi[INVESTIGATOR_841223] 
I Mild 28-35 No Wrinkles Early Photoaging: mild pi[INVESTIGATOR_61361], no keratosis, 
minimal wrinkles, minimal or no makeup  
II Moderate 35-50 Wrinkles in 
motion  Early to Moderate Photoaging: Early brown spots 
visible, keratosis palpable bu t not visible, parallel smile 
lines begin to appear, wears some foundation  
III Advanced 50-[ADDRESS_1168881] Advanced Photoaging: Obvious discolorations, visible 
capi[INVESTIGATOR_11037] (telangiectasias),  visible keratosis, wears 
heavier foundation always  
IV Severe 60-75 Only wrinkles Severe Photoaging; Yellow-gray skin color, prior skin 
malignancies, wrinkles throughout -no normal skin, 
cannot wear makeup because it cakes and cracks  
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 43 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL Appendix C: Fitzpatrick Skin Type 
 
 
 
  Fitzpatrick Skin Type 
Skin 
Type Usual Characteristics Descent/Ethnicity Burn/Tan 
I White; very fair; red or blond 
hair; blue eyes, often freckles. Redheads, Celtics, Irish, 
Scottish  Always burns, never tans 
II White; fair; red or blonde hair; 
blue, hazel or green eyes, 
often freckles.  Caucasians Usually burns, tans with 
difficulty  
III Cream white; fair with any eye 
or hair color  Caucasians Sometimes mild burn, 
gradually tans  
IV Brown; typi[INVESTIGATOR_841224], 
Caucasian skin  Mediterranean, Asians, 
Hispanics, American Indian
 Rarely burns, tans with ease 
V Dark browns; Middle Eastern 
skin types  Middle Eastern, East 
Indian, some Hispanics, some African Americans, 
so
me Asians Very rarely burns, tans very 
easily  
VI Black Usually African Never burns, tans very easily 
Protocol [V01-CBT-401] Bausch Health Americas, Inc.
 
Version 3.0 09/13/2021 CONFIDENTIAL
Protocol [V01-CBT-401] Bausch Health Americas, Inc.
 
Page 45 of 49  
Version 3.0 09/13/2021 CONFIDENTIAL
Protocol [V01-CBT-401] Bausch Health Americas, Inc.
 
Page 46 of 49  
Version 3.0 09/13/2021 CONFIDENTIAL
Protocol [V01-CBT-401] Bausch Health Americas, Inc.
 
Page 47 of 49  
Version 3.0 09/13/2021 CONFIDENTIAL
Protocol [ V01-CBT-401] Bausch Health Americas, Inc.
Page 48 of 49  
Version 3.0 09/13/2021 CONFIDENTIAL
Protocol [V01-CBT-401]   Bausch Health Americas, Inc.  
 
Page 49 of 49  
Version 3.0 09/13/2021  CONFIDENTIAL Appendix F: Patient Skin Response Seven-Day Diary 
 
Using the severity scale, please rate the following conditions after your treatment: 
Answer for all conditions each day:   
  0= None 1= Mild 2= Moderate 3= Severe Rating 
      
Day 1 Erythema (redness)   
 Edema (swelling)   
 Heat sensation after treatment   
      
Day 2 Erythema (redness)   
 Edema (swelling)   
 Heat sensation after treatment   
      
Day 3 Erythema (redness)   
 Edema (swelling)   
 Heat sensation after treatment   
      
Day 4 Erythema (redness)   
 Edema (swelling)   
 Heat sensation after treatment   
      
Day 5 Erythema (redness)   
 Edema (swelling)   
 Heat sensation after treatment   
      
Day 5 Erythema (redness)   
 Edema (swelling)   
 Heat sensation after treatment   
      
Day 6 Erythema (redness)   
 Edema (swelling)   
 Heat sensation after treatment   
      
Day 7 Erythema (redness)   
 Edema (swelling)   
 Heat sensation after treatment   
      
 
 